Alphamab Oncology (FRA:3NK)

Alphamab Oncology Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 9, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	1,168	419	742	1,218	1,437	1,605
Market Cap Growth	190.60%	-43.55%	-39.08%	-15.24%	-10.46%	11.71%
Enterprise Value	1,002	268	580	1,052	1,219	1,347
Last Close Price	1.18	0.44	0.75	-	-	-
PE Ratio	42.19	19.03	-	-	-	-
PS Ratio	12.50	4.95	26.58	53.81	71.10	-
PB Ratio	5.30	1.73	3.48	5.76	5.55	5.64
P/TBV Ratio	5.30	1.73	3.48	5.76	5.55	5.64
P/FCF Ratio	45.14	16.61	-	-	-	-
P/OCF Ratio	38.30	14.91	-	-	-	-
EV/Sales Ratio	10.55	3.16	20.76	46.46	60.34	-
EV/EBITDA Ratio	31.95	12.24	-	-	-	-
EV/EBIT Ratio	44.08	20.04	-	-	-	-
EV/FCF Ratio	38.73	10.62	-	-	-	-
Debt / Equity Ratio	0.15	0.10	0.15	0.22	0.34	0.10
Debt / EBITDA Ratio	1.05	1.04	-	-	-	-
Debt / FCF Ratio	1.26	0.98	-	-	-	-
Asset Turnover	0.35	0.29	0.10	0.07	0.06	-
Inventory Turnover	0.83	0.75	0.77	0.72	0.06	-
Quick Ratio	4.76	6.41	5.55	3.72	3.22	6.52
Current Ratio	4.98	6.74	5.84	3.88	3.32	6.67
Return on Equity (ROE)	13.37%	9.49%	-13.04%	-19.00%	-19.91%	-18.21%
Return on Assets (ROA)	5.22%	2.88%	-9.50%	-11.21%	-9.72%	-9.32%
Return on Capital (ROIC)	5.76%	3.20%	-10.55%	-12.25%	-10.38%	-9.89%
Return on Capital Employed (ROCE)	9.40%	5.10%	-17.30%	-25.00%	-20.10%	-17.70%
Earnings Yield	2.37%	5.25%	-3.62%	-3.63%	-3.97%	-3.34%
FCF Yield	2.22%	6.02%	-4.11%	-4.79%	-4.61%	-3.42%
Buyback Yield / Dilution	-3.37%	-2.53%	-2.50%	-0.11%	-0.62%	-73.29%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.